Spexis sells antibiotics programme to Basilea
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.<br /><br />
Novartis AG to buy immunology specialist Calypso Biotech BV
<a title="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Calypso Biotech BV</a> has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up […]
GLP1 agonists: FDA investigates suicide risk
Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. <br /><br />
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Roche presents restistance-breaking antibiotic
Hoffmann-La Roche AG has published details on <i>the mechanism of action of its Phase I antibiotic Zosurabalpin</i> (RG6006) that kills the carbapenem-resistant bug<i> Acinetobacter baumannii</i>. <br />.
Alfasigma SpA signs €170m deal with Galapagos NV
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. <div title="Page 1" class="page"><div class="layoutArea"><div class="column"></div></div></div>